Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.7.0.1
Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Revenue:        
Grant and licensing revenue $ 411,250 $ 435,490
Operating expenses:        
Research and development 2,151,932 1,776,325 3,964,833 5,434,333
General and administrative 1,582,581 1,083,298 3,109,596 2,114,456
Total operating expenses 3,734,513 2,859,623 7,074,429 7,548,789
Loss from operations (3,323,263) (2,859,623) (6,638,939) (7,548,789)
Non-operating income (expenses)        
Interest income 6,466 7,854 11,687 18,955
Other income (expense), net 7,716 (57,166) 77,443 22,535
Interest expense (123,832) (259,954)
Total non-operating income (expenses), net 14,182 (173,144) 89,130 (218,464)
Net loss (3,309,081) (3,032,767) (6,549,809) (7,767,253)
Net loss - non-controlling interest (90,166) (107,546) (140,956) (282,428)
Net loss attributable to Heat Biologics, Inc. $ (3,218,915) $ (2,925,221) $ (6,408,853) $ (7,484,825)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted $ (0.09) $ (0.17) $ (0.21) $ (0.56)
Weighted-average number of common shares used in net loss per share attributable to common stockholders-basic and diluted 35,244,833 17,524,641 31,124,119 13,324,641
Other comprehensive loss:        
Net loss $ (3,309,081) $ (3,032,767) $ (6,549,809) $ (7,767,253)
Unrealized (loss)/gain on foreign currency translation (9,660) 49,233 (76,035) (26,574)
Total other comprehensive loss (3,318,741) (2,983,534) (6,625,844) (7,793,827)
Comprehensive loss attributable to non-controlling interest (90,166) (107,546) (140,956) (282,428)
Comprehensive loss $ (3,228,575) $ (2,875,988) $ (6,484,888) $ (7,511,399)